Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

675

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

January 20, 2022

Study Completion Date

January 20, 2022

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

Rifampicin

10mg/kg

DRUG

Isoniazid

5mg/kg

DRUG

Pyrazinamide

25mg/kg

DRUG

Ethambutol

15mg/kg

DRUG

Linezolid

600mg

DRUG

Clofazimine

200mg

DRUG

Rifapentine

1200mg

DRUG

Levofloxacin

1000mg

DRUG

Bedaquiline

400mg once daily for 2 weeks then 200mg 3x a week

DRUG

Rifampicin

35mg/kg

Trial Locations (18)

Unknown

National Institute of TB and Respiratory Diseases, New Delhi

Universitas Padjadjaran, Bandung

Persahbahatan Hospital, Jakarta

Wahidin Sudirohusodo Hospital, Makassar

Saiful Anwar Hospital, Malang

Soetomo General Hospital, Surabaya

Perpetual Succour Hospital, Cebu

De La Salle Health Sciences Institute, Manila

Lung Center Philippines, Manila

Philippines Tuberculosis Society Incorporated (PTSI), Manila

Tropical Disease Foundation, Manila

Quezon Institute, Quezon City

National University Hospital, Singapore

King Chulalongkorn Memorial Hospital, Bangkok

Central Chest Institute of Thailand, Nonthaburi

Infectious Diseases Institute, Kampala

Joint Clinical Research Centre, Kampala

Joint Clinical Research Centre, Mbarara

All Listed Sponsors
collaborator

National University Hospital, Singapore

OTHER

collaborator

Singapore Clinical Research Institute (SCRI)

UNKNOWN

lead

University College, London

OTHER

NCT03474198 - Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis | Biotech Hunter | Biotech Hunter